Document is current
Any future updates will be listed below
-
Authors
Kornfield, Sara L.
Farber, Emma
Reisinger, Erica M.
Bhadra-Heintz, Nia
Roder, Navid
Hamm, Rebecca F.
Kranzler, Henry
Mandell, David S.
Becker-Haimes, Emily
-
Funding
Funding for this research was provided by:
National Institute of Drug Abuse (R21DA058815)
National Institute of Drug Abuse (R21DA058815)
National Institute of Drug Abuse (R21DA058815)
National Institute of Drug Abuse (R21DA058815)
National Institute of Drug Abuse (R21DA058815)
National Institute of Drug Abuse (R21DA058815)
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 23 January 2026
First Online: 24 February 2026
Declarations
:
: This study was approved by the Institutional Review Board of the University of Pennsylvania Perelman School of Medicine.
: Not Applicable.
: HK is a member of advisory boards for Altimmune and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals and Altimmune; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Imbrium, Indivior, Kinnov, Lilly, Otsuka, and Pear; and an inventor on U.S. provisional patent 63/710,270 “Multi-ancestry Genome-wide Association Meta-analysis of Buprenorphine Treatment Response,” filed 29 October 2024. The rest of the authors declare no competing interests.
